News Related to Selective RET Kinase Inhibitor

Related coverage linked through entity extraction aliases.

Experimental Cancer Drugs Show Promise in Prostate and Lung Cancer Trials

Mar 25, 2026

An experimental immunotherapy drug shows tumor shrinkage in prostate cancer patients, while Eli Lilly's selpercatinib reduces recurrence risk in early-stage lung cancer. A separate study reveals persistent racial disparities in curative treatment for lung cancer patients.

Selpercatinib Meets Primary Endpoint in Phase III Adjuvant NSCLC Trial

Feb 16, 2026

Eli Lilly's Retevmo (selpercatinib) demonstrated statistically significant event-free survival improvement in the Phase III LIBRETTO-432 trial for early-stage RET fusion-positive non-small cell lung cancer.